Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound 10m
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Compound 10m is a novel pyrrolidine aryl carboxamide derivative being investigated as a potential chemotherapeutic agent for hepatocellular carcinoma (HCC). It demonstrates anticancer potency comparable to OSU-2S and is approximately two-fold more potent than Sorafenib in HCC. The drug's mechanism of action involves inducing apoptosis in cancer cells, possibly through the activation of Protein Kinase C delta (PKCδ), and it also contributes to cell cycle arrest and the inhibition of cancer cell migration, while exhibiting a favorable safety profile on normal cells.
- Other names
- 1-(4-chlorophenyl)-n-(4-((5-cyclopropyl-1h-pyrazol-3-yl)amino)phenyl)pyrrolidine-3-carboxamide
02
Targets
PRKCD (Protein kinase C delta)
Beyond the preview
Go deeper on compound 10m.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound 10m.